Vertex Pharmaceuticals and CRISPR Therapeutics submit FDA rolling Biologics License Applications for gene editing-based medicine
April 4, 2023Research and Development
US-based Vertex Pharmaceuticals and Swiss CRISPR Therapeutics have announced the completion of their rolling Biologics License Applications (BLAs) to the …
FDA publishes report stating Global Pharma’s eye drops broke safety norms
April 4, 2023Medical Communications
The FDA has published a report revealing that Global Pharma’s plant in India’s Chennai city failed to achieve safety norms …
InnoCare announced first subject dosed in clinical trial of novel targeted protein degrader ICP-490
April 4, 2023Medical Communications
InnoCare has announced that the first subject has been dosed in its clinical trial of its novel targeted protein degrader …
Merck receives FDA approval for Keytruda in combination with Padcev to treat bladder cancer
April 4, 2023Medical Communications
Merck (known as MSD globally) has announced that it has received FDA approval for Keytruda in combination with Padcev for …
Théa Open Innovation and Galimedix announce partnership for development and commercialisation of GAL-101
April 3, 2023Sales and Marketing
Théa Open Innovation (TOI) and Galimedix have announced that they have signed a licensing agreement granting TOI exclusive rights for …
aVaxziPen announces positive data for multiple diseases with novel needle-free vaccine
April 3, 2023Research and Development
aVaxziPen, a biotech company focusing on the development of a novel needle-free vaccine delivery platform, has announced that it will …
Pixium Vision’s Prima System granted FDA Breakthrough Device Designation
April 3, 2023Medical Communications
French bioelectronics company Pixium Vision has been granted Breakthrough Device Designation by the FDA for its Prima System. Prima …
AstraZeneca’s NMOSD treatment recommended marketing authorisation by CHMP
April 3, 2023Medical Communications
Pharma giant AstraZeneca has been given a recommendation by the EU’s Committee for Medicinal Products (CHMP) for marketing authorisation for …
CrestOptics launches CICERO system to provide all-in-one solution for widefield and spinning disk confocal microscopy
April 3, 2023Business Services
Rome, IT, 03 April, 2023: CrestOptics S.p.A., a manufacturer of high-end microscopy solutions and advanced systems for fluorescence microscopy and …
Sequana Medical announces submission of Investigational New Drug (IND) application for DSR® 2.0 for treatment of congestive heart failure
April 3, 2023Business Services
Ghent, Belgium – 03 April 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana
Novo Nordisk Foundation to support crucial education of health professionals in India and East Africa with up to DKK 1bn (USD 140m)
April 3, 2023Business Services
Lack of access to qualified health personnel combined with an alarming prevalence of noncommunicable diseases (NCDs) such as cardiometabolic diseases …
Redx Confirms Proposed Business Combination with Jounce has Formally Lapsed
April 3, 2023Business Services
Alderley Park, UK, 3 April 2023 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, …
Almirall: The New England Journal of Medicine (NEJM) and the British Journal of Dermatology (BJD) publish Ph3 data evaluating lebrikizumab efficacy and safety in moderate-to-severe atopic dermatitis
March 31, 2023Business Services Almirall, Dermatology, dermatology, lebrikizumab
BARCELONA, Spain. March 31, 2023 – Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, announced today the …
HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer
March 31, 2023Business Services
Hong Kong, Shanghai & Florham Park, NJ — Friday, March 31, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) today announces that …
Abbott gains FDA approval for Epic Max tissue valve for the treatment of aortic valve disease
March 31, 2023Medical Communications
Abbott has announced that the FDA has approved its Epic Max stented tissue valve to treat patients with aortic regurgitation …
First over-the-counter opioid overdose treatment approved by FDA
March 31, 2023Medical Communications
The FDA has announced that it has approve Narcan, 4mg naloxone hydrochloride nasal spray for over-the-counter (OTC), non-prescription use. This …
NEC streamlines AI drug development with subsidiary reshuffle
March 31, 2023Medical Communications
Japan-based NEC Corporation has announced that it is realigning its subsidiaries in order to streamline its AI drug development services. …
Nanoscope Therapeutics announces positive results from phase 2b trial in Retinitis Pigmentosa
March 31, 2023Medical Communications
US-based Nanoscope Therapeutics has announced topline results from its phase 2b RESTORE clinical trial. Currently, patients with vision loss due …
Expansion of Scientific Affairs Group
March 30, 2023Business Services
Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an …
Roz Bekker appointed Managing Director of Janssen UK & Ireland
March 30, 2023Business Services
High Wycombe, UK, 30 March 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson are pleased to introduce Roz …
Latest content
FibroFind appoints Lee Borthwick as CEO
